Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Federal Trade Commission
Julphar
Queensland Health
Moodys
Baxter
Cantor Fitzgerald
Fuji

Generated: May 23, 2018

DrugPatentWatch Database Preview

Sebela Ireland Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for SEBELA IRELAND LTD, and what generic alternatives to SEBELA IRELAND LTD drugs are available?

SEBELA IRELAND LTD has seventeen approved drugs.

There are seven US patents protecting SEBELA IRELAND LTD drugs.

There are seventy-two patent family members on SEBELA IRELAND LTD drugs in thirty-two countries and two supplementary protection certificates in two countries.

Summary for Sebela Ireland Ltd
International Patents:72
US Patents:7
Tradenames:12
Ingredients:10
NDAs:17

Drugs and US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd PRAMOSONE hydrocortisone acetate; pramoxine hydrochloride CREAM;TOPICAL 085368-001 Approved Prior to Jan 1, 1982 RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Sebela Ireland Ltd BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 AB RX Yes Yes 9,393,237 ➤ Try a Free Trial ➤ Try a Free Trial
Sebela Ireland Ltd IMURAN azathioprine TABLET;ORAL 016324-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Sebela Ireland Ltd NAFTIN naftifine hydrochloride GEL;TOPICAL 204286-001 Jun 27, 2013 RX Yes Yes 8,778,365 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Sebela Ireland Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sebela Ireland Ltd ONMEL itraconazole TABLET;ORAL 022484-001 Apr 29, 2010 8,591,948 ➤ Try a Free Trial
Sebela Ireland Ltd RIDAURA auranofin CAPSULE;ORAL 018689-001 May 24, 1985 4,225,597 ➤ Try a Free Trial
Sebela Ireland Ltd BRISDELLE paroxetine mesylate CAPSULE;ORAL 204516-001 Jun 28, 2013 5,874,447 ➤ Try a Free Trial
Sebela Ireland Ltd MOTOFEN atropine sulfate; difenoxin hydrochloride TABLET;ORAL 017744-002 Approved Prior to Jan 1, 1982 3,646,207 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SEBELA IRELAND LTD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-12-02
➤ Subscribe Capsules 7.5 mg ➤ Subscribe 2014-04-07

Non-Orange Book US Patents for Sebela Ireland Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,452,173 Topical compositions and methods for making and using same ➤ Try a Free Trial
9,149,431 Itraconazole compositions with improved bioavailability ➤ Try a Free Trial
5,874,447 4-Phenylpiperidine compounds for treating depression ➤ Try a Free Trial
9,446,131 Topical compositions and methods for making and using same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Sebela Ireland Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/012 United Kingdom ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0038 France ➤ Try a Free Trial PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Accenture
Fish and Richardson
Federal Trade Commission
Express Scripts
Julphar
US Department of Justice
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.